AACR22: RACE Act increases number of cancer drugs investigated for use in pediatric patients

The Research to Accelerate Cures and Equity (RACE) for Children Act has resulted in increased requirements for more recently approved cancer drugs to be studied for potential use in pediatric patients in its first year of implementation. The RACE Act took effect on 18 August 2020 and requires all new adult oncology therapeutics under consideration for approval by the US FDA to be evaluated for safety and efficacy in pediatric cancers if the treatment is directed at a molecular target relevant to pediatric cancer, including therapeutics with an orphan drug designation. Prior to the RACE Act, pharmaceutical companies were not...